


This article was downloaded by: [Pennsylvania State University]

On: 20 March 2013, At: 07:22

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn19>

5-[2-(2-Methoxy)bornyl]tetrazole as Catalyst for Diastereoselective Synthesis of 2'-Deoxy Dinucleoside (3', 5')-Methylphosphonates

Peter Schell^a & Joachim W. Engels^a

^a Institute of Organic Chemistry, Johann Wolfgang Goethe-University, Marie-Curie-Str. 11, D-60439, Frankfurt, Germany
Version of record first published: 22 Aug 2006.

To cite this article: Peter Schell & Joachim W. Engels (1997): 5-[2-(2-Methoxy)bornyl]tetrazole as Catalyst for Diastereoselective Synthesis of 2'-Deoxy Dinucleoside (3', 5')-Methylphosphonates, *Nucleosides and Nucleotides*, 16:5-6, 769-772

To link to this article: <http://dx.doi.org/10.1080/07328319708002948>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**5-[2-(2-METHOXY)BORNYL]TETRAZOLE AS CATALYST FOR
DIASTEREOSELECTIVE SYNTHESIS OF
2'-DEOXY DINUCLEOSIDE (3', 5')-METHYLPHOSPHONATES**

Peter Schell and Joachim W. Engels*


Institute of Organic Chemistry, Johann Wolfgang Goethe-University, Marie-Curie-Str. 11,
D-60439 Frankfurt am Main, Germany

ABSTRACT: The synthesis of 5-[2-(2-methoxy)bornyl]tetrazole **1** is described. **1** is used as catalyst for the diastereoselective synthesis of some 2'-deoxy dinucleoside (3', 5')-methylphosphonates in solution.

INTRODUCTION

Oligonucleoside methylphosphonates are well established in the antisense strategy to control gene expression in mammalian cells. They are stable against degradation by cellular nucleases and are taken up intact by cells in culture.^{1,2} Due to the chirality at phosphorus oligonucleoside methylphosphonates containing *n* methylphosphonate linkages consist of a mixture of 2^{*n*} diastereomers.³ It has been demonstrated that methylphosphonate oligonucleosides containing linkages with *R_p* configuration have higher *T_m* values than the corresponding oligonucleotides containing linkages with *S_p* configuration.^{4,5} Recently, an antisense application of oligonucleotides containing chirally pure *R_p* methylphosphonates has been reported.⁶

For developing oligonucleoside methylphosphonates into therapeutic agents a simple and convenient method for their stereocontrolled synthesis is necessary. Some methods for this purpose have been summarized⁷ or were published recently.⁸⁻¹¹ Most of these methods use diastereomerically pure precursors, which are coupled in a stereoselective or stereospecific manner using P(V) chemistry. We are strongly interested in the phosphoramidite approach because it is well established and effective for solid phase synthesis. Previously we studied the effect of chiral amines derived from proline in the phosphoramidite component.⁸ Due to the structural properties of the methylphosphonates the tetrazole catalyst is the remaining possibility to influence the coupling reaction. Here we present the use of 5-[2-(2-methoxy)bornyl]tetrazole **1**¹² to



i: 1) $\text{HC}(\text{OCH}_3)_3$, MeOH, *p*-TsOH, reflux, 2) Na, reflux; ii: $\text{BF}_3 \cdot \text{OEt}_2$, diethylether, TMSCN; iii: 1) *n*- Bu_3SnN_3 , xylene, reflux, or *n*- Bu_3SnCl , NaN_3 , xylene, reflux, 2) HCl

SCHEME 1

achieve diastereoselectivity during the coupling reaction starting with a diastereomeric mixture of the commercially available methylphosphoramidites.


RESULTS AND DISCUSSION

Both enantiomers and the racemic mixture of **1** were used in the coupling reaction. The synthesis of **1** is summarized in scheme 1.

The synthesis starts from camphor **2** which was reacted with trimethylorthoformate in methanol to yield dimethylketal **3**.¹³ Unreacted **2** has to be removed by treatment with sodium prior to distillation. **3** was treated with borontrifluoride etherate and trimethylsilylcyanide in diethylether¹⁴ to yield **4** as a mixture of two diastereomers in a 8 : 1 ratio. **4** was converted to title compound **1** in boiling xylene by tri-*n*-butyltinazide which was prepared independently or generated in situ.¹⁵ Treatment with HCl liberated **1**.

Then **1** was used as catalyst for the synthesis of 2'-deoxy dinucleoside methylphosphonates as outlined in scheme 2. The results of the coupling reactions are summarized in table 1.

The coupling reactions with **1** as catalyst were compared with the corresponding reactions catalyzed by 1*H*-tetrazole. Interestingly, not in all cases an effect of **1** on the diastereomeric composition was observed. The reaction seems to be dependent on the



SCHEME 2

TABLE 1

Catalyst	1 <i>H</i> -tetrazole	1a	1b	1c
Dimer	R _p (ppm) [#] / S _p (ppm)	R _p (ppm) / S _p (ppm)	R _p / S _p	R _p / S _p
T-T	46 (31,97) / 54 (32,80)	45 (31,97) / 55 (32,80)	46 / 54	44 / 56
T-A	49 (32,30) / 51 (32,71)	40 (32,43) / 60 (32,81)	39 / 61	37 / 63
A-T	53 (32,11) / 47 (32,89)	54 (31,95) / 46 (32,70)	52 / 48	51 / 49
A-A	59 (32,37) / 41 (32,69)	48 (32,34) / 52 (32,64)		42 / 58
G-T	50 (32,17) / 50 (32,54)	64 (32,22) / 36 (32,53)	63 / 37	52 / 48
G-A *	46 (32,48) / 54 (32,58)	35 (32,60) / 65 (32,72)	38 / 62	41 / 59

[#] ³¹P chemical shift values (CDCl₃) of the corresponding signals. The crude reaction mixtures were measured. Therefore chemical shift values may vary slightly. * In this case the fast isomer (tlc) (normally R_p) showed the higher chemical shift value. Therefore the assignment of the two diastereomers may be reversed.

nature of the nucleosides. The chirality of the catalyst plays less a role, because there are minor differences in the diastereoselectivity comparing the syntheses of one dimer catalyzed by the tetrazoles **1a-c**.

In conclusion, chiral tetrazoles are interesting candidates for the diastereoselective synthesis of methylphosphonates. Studies on the mechanism of the tetrazole catalyzed coupling reaction and further improvement of the catalyst are in progress.

General procedure for the coupling reaction: 0,03 mmole methylphosphoramidite, 0,03 mmole 3'-O-TBDPS protected nucleoside and 0,12 mmole **1** were dried together in vacuo over P₂O₅ for at least 48 h. The reaction was started by addition of 600 µl of anhydrous CH₂Cl₂ to this mixture. After 2 h the reaction was stopped

by addition of 50 μ l of *t*-BuOOH. After 10 min. at room temperature the mixture was diluted with CH_2Cl_2 and extracted with a 1:1 mixture of 5 % aqueous NaHCO_3 and 5 % aqueous Na_2SO_3 . The aqueous layer was extracted twice with CH_2Cl_2 and the organic layer was dried over Na_2SO_4 . After evaporation to dryness the mixture was dissolved in CDCl_3 and measured by ^{31}P spectroscopy.

REFERENCES

1. Miller P.S., *Bio/Technology*, **1991**, 9, 358-362
2. Uhlmann E., Peyman A., *Chem. Rev.*, **1990**, 90, 543-584
3. For a recent review on the chirality problem in P-substituted oligonucleotides see: Lebedev A.V., Wickstrom E., *Perspectives in Drug Discovery and Design*, **1996**, 4, 17-40
4. Lesnikowski Z.J., Jaworska M., Stec W.J., *Nucleic Acids Res.*, **1990**, 18, 2109-2115
5. Vyazovkina E.V., Savchenko E.V., Lokhov S.G., Engels J.W., Wickstrom E., Lebedev A.V., *Nucleic Acids Res.*, **1994**, 22, 2404-2409
6. Brown B.D., Cotter F., Almazan M., Dizik M., Jaeger J., Woodle M.C., Marvin B., Daily W., Riley T.A., Arnold L.J., *XII International Roundtable. Nucleosides, Nucleotides And Their Biological Applications, La Jolla, California, September 15-19, 1996*, PPI 90
7. Lesnikowski Z.J., *Bioorganic Chemistry*, **1993**, 21, 127-155
8. Rosmanitz P., Eisenhardt S., Bats J.W., Engels J.W., *Tetrahedron*, **1994**, 50, 5719-5734
9. Wozniak L.A., Pyzowski J., Wieczorek M., Stec W.J., *J. Org. Chem.*, **1994**, 59, 5843-5846
10. Le Bec C., Wickstrom E., *J. Org. Chem.*, **1996**, 61, 510-513
11. Vaghefi M.M., Langley K.A., *Tetrahedron Lett.*, **1996**, 37, 4853-4856
12. Hirose M., Hayakawa Y., *1. International Antisense Conference of Japan, December 4-7, 1994*, P2-17
13. Wiberg K.B., Cunningham W.C., *J. Org. Chem.*, **1990**, 55, 679-684
14. Utimoto K., Wakabayashi Y., Shishiyama Y., *Tetrahedron Lett.*, **1981**, 22, 4279-4280
15. Sisido K., Nabika K., Isida T., *J. Organometal. Chem.*, **1971**, 33, 337-346